NCT06705751

Brief Summary

Anomalous aortic origin of the coronary arteries (AAOCA) is a rare congenital disease and one of the leading causes of sudden cardiac deaths (SCD) in young athletes but also has a lethal presentation in adult age with myocardial infarction, even if not related to obstructive coronary arteries. Unfortunately, diagnostic imaging techniques, invasive assessment, and provocative stress tests have shown low sensitivity and specificity in detecting inducible ischemia, and a multimodality assessment is then necessary. Innovative tools have been developed in the medical field using computer-based simulation, 3-dimensional reconstruction, machine learning, and artificial intelligence (AI). With the application of such new technologies, we aim to fill the gap of knowledge and the diagnostic limitation regarding risk stratification for most subjects with AAOCA. This work seeks to enhance, fasten, and personalize the clinical diagnosis of AAOCA by integrating anatomical measurements, clinical data, and biomechanical patient-specific features. The SMART study will set a system to automatically segment and classify coronary arteries with AAOCA from computerized tomography angiography (CTA) by artificial intelligence (AI). Segmentation will feed a 3D model of the aortic root and coronary artery for biomechanical assessment through finite element analysis (FEA). This will allow us to assess the location of possible coronary artery compression under an effort condition. These in-silico results, the anatomical features measured by AI, and the clinical data will be integrated into a risk model to estimate the hazard risk of adverse events such as SCD or myocardial infarction. This workflow will be framed in an IT system to allow a web-based remote diagnostic service. Thanks to the proposed multidisciplinary approach, SMART aims to overcome the current diagnostic limitations related to the reduced ability of functional stress tests to detect ischemia. Potentially helping in patient-specific risk stratification, SMART is also thought to provide a way to get a first diagnostic indication about AAOCA being accessible from any hospital, fostering the diffusion of peripheral territorial support to the diagnosis and treatment of such rare disease.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
9mo left

Started Sep 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Sep 2024Feb 2027

Study Start

First participant enrolled

September 12, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 17, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 26, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

April 15, 2026

Status Verified

March 1, 2026

Enrollment Period

1.9 years

First QC Date

October 17, 2024

Last Update Submit

April 10, 2026

Conditions

Keywords

AAOCACTIMAGE SEGMENTATIONACAOS

Outcome Measures

Primary Outcomes (1)

  • Analysis of Autonomic Test Data

    Beat-to-beat series will be extracted from recorded signals to derive indices related to autonomic, cardiovascular, cerebrovascular, and peripheral microcirculation control during REST and STAND phases. The cardiac period will be defined as the interval between consecutive R peaks (RR- msec) in the ECG, with systolic (SAP - mmHg) and diastolic blood pressure (DAP - mmHg) calculated as the maximum and minimum pressures between these peaks. Random sequences of 250 beats will be selected from each recording and manually verified for corrections. Ectopic beats will be adjusted using cubic spline interpolation. Indices of cardiovascular control will be derived from time-domain variability measures, and spectral density will be estimated using a parametric autoregressive approach. Analyses will be conducted using software developed in Matlab and C++.

    two years

Study Arms (1)

Prospective study

EXPERIMENTAL

The prospective phase aims to validate the entire model developed during the retrospective phase and to evaluate the role of autonomic response in subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA). The prospective recruitment of the cohort of AAOCA patients for autonomic assessment and validation will span the entire duration of the study. Our objective is to recruit 38 patients with AAOCA to obtain consistent and uniform data from at least 32 participants. Patients in this cohort will undergo an active standing test to elicit an autonomic response, and the results will be compared with reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions.

Diagnostic Test: Autonomic response in AAOCA

Interventions

Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited. Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch. The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions.

Prospective study

Eligibility Criteria

Age6 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Adult and pediatric patients (age \> 6 years) with anomalous coronary origin from the aorta (AAOCA).
  • Patients in spontaneous sinus rhythm.
  • Signed informed consent.

You may not qualify if:

  • Patients with acute and chronic inflammatory conditions such as chronic liver disease, chronic kidney failure (creatinine \> 1.5 mg/dl), and thyroid disorders.
  • Patients with arrhythmias, absence of sinus rhythm.
  • Contraindications to autonomic testing.
  • Patients with a known allergy to materials in recording devices.
  • Female patients who are pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Policlinico San Donato

San Donato Milanese, Italia, 20097, Italy

RECRUITING

MeSH Terms

Conditions

Death, Sudden, CardiacMyocardial IschemiaAngina Pectoris

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular DiseasesDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and SymptomsVascular DiseasesChest PainPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: The prospective part involves the enrollment of patients with AAOCA at the San Donato Polyclinic in order to validate the entire system developed in the retrospective part and to assess the role of autonomic response in individuals with AAOCA. A total of 38 subjects with AAOCA will be recruited and will undergo an active standing test. For this prospective sample, demographic, clinical data, and DICOM files from diagnostic CT angiographies for AAOCA (previously performed for medical reasons) will also be collected to be used as a validation set for the created tool. The patients in this cohort will undergo an active standing test to evoke an autonomic response. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure (BP), and respiration in both supine and prone positions. The retrospective part includes four main tasks: development of U-NET and AI, FEA simulation, risk prediction model, and creation of the online platform.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2024

First Posted

November 26, 2024

Study Start

September 12, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

April 15, 2026

Record last verified: 2026-03

Locations